Adial Pharmaceuticals, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
4Adial Pharmaceuticals's Business Model
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
About Adial Pharmaceuticals
Website: https://www.adialpharma.com
CEO (Chief Executive Officer): Mr. Cary John Claiborne MBA
IPO date: 2018-07-27
Contact
Country: US
Address: 1180 Seminole Trail
City: Charlottesville
State: VA
Phone: 434 422 9800
Zip Code: 22901
Other
CIK: 0001513525
ISIN: US00688A2050
CUSIP: 00688A106
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
